Ehsan Rahimy
Palo Alto Medical Foundation · 234 works · 6,008 citations · h-index 34
Top works
- Paracentral Acute Middle Maculopathy
- Grader Variability and the Importance of Reference Standards for Evaluating Machine Learning Models for Diabetic Retinopathy
- Acute macular neuroretinopathy: A comprehensive review of the literature
- Spectrum of Retinal Vascular Diseases Associated With Paracentral Acute Middle Maculopathy
- Using a Deep Learning Algorithm and Integrated Gradients Explanation to Assist Grading for Diabetic Retinopathy
- The Spectrum of Superficial and Deep Capillary Ischemia in Retinal Artery Occlusion
- Paracentral Acute Middle Maculopathy
- Paracentral acute middle maculopathy spectral-domain optical coherence tomography feature of deep capillary ischemia
- Paracentral Acute Middle Maculopathy in Nonischemic Central Retinal Vein Occlusion
- Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: Evaluation and management
- Assessing Deep Retinal Capillary Ischemia in Paracentral Acute Middle Maculopathy by Optical Coherence Tomography Angiography
- Optical Coherence Tomography Angiography and En Face Optical Coherence Tomography Features of Paracentral Acute Middle Maculopathy
- Baseline Choroidal Thickness as a Predictor for Response to Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema
- Deep learning applications in ophthalmology
- MULTILAYERED PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- Robot-assisted intraocular surgery: development of the IRISS and feasibility studies in an animal model
- Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis).
- Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema
- Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept
- PROSPECTIVE EVALUATION OF THE INCIDENCE AND RISK FACTORS FOR THE DEVELOPMENT OF RPE TEARS AFTER HIGH- AND LOW-DOSE RANIBIZUMAB THERAPY